Combat Drugs is currently trading at Rs. 23.60, up by 0.30 points or 1.29% from its previous closing of Rs. 23.30 on the BSE.
The scrip opened at Rs. 23.60 and has touched a high and low of Rs. 24.40 and Rs. 23.60 respectively.
The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 30.40 on 14-Nov-2018 and a 52 week low of Rs. 18.95 on 03-Jan-2019.
Last one week high and low of the scrip stood at Rs. 28.45 and Rs. 23.30 respectively. The current market cap of the company is Rs. 18.64 crore.
The promoters holding in the company stood at 58.00%, while Institutions and Non-Institutions held 0.02% and 41.98% respectively.
Combat Drugs has received approval for acquisition of a Limited Liability Company (LLC) based in the United States of America. The LLC is operating in the field of Information Technology Services specializing in ERP Solutions, Business Intelligence, Data Warehousing, Software Development, Consulting, Programming and Offshore Development. The Board of Directors of the Company at its meeting held on August 12, 2019 has approved the same.
The Board with a view of making the company's global presence in the field of Pharma and Information Technology, is considering the proposal of the acquisition of LLC, subject to Due Diligence of the LLC and its authorized representatives and the Feasibility and Viability report.
Combat Drugs manufactures and markets pharmaceutical formulations in India. The company offers its products in various forms, such as tablets, capsules, liquid orals, and ointments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: